In-vitro anticancer profile of recent ruthenium complexes against liver cancer

References

Alsaeedi, M. S.; Babgi, B. A.; Abdellattif, M. H.; Jedidi, A.; Humphrey, M. G.; Hussien, M. A. DNA-binding capabilities and anticancer activities of ruthenium (II) cymene complexes with (Poly) cyclic aromatic diamine ligands. Molecules 2021, 26(1), 76.10.3390/molecules26010076Suche in Google Scholar PubMed PubMed Central

Bosch, F. X.; Ribes, J.; Díaz, M.; Cléries, R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127(5, Suppl. 1), S5–S16. https://doi.org/10.1053/j.gastro.2004.09.011.Suche in Google Scholar PubMed

Bailleux, C.; Eberst, L.; Bachelot, T. Treatment strategies for breast cancer brain metastases. Br. J. Cancer 2021, 124(1), 142–155. https://doi.org/10.1038/s41416-020-01175-y.Suche in Google Scholar PubMed PubMed Central

Bergamo, A.; Sava, G. Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs. Dalton Trans. 2011, 40(31), 7817–7823.https://doi.org/10.1039/c0dt01816c.Suche in Google Scholar PubMed

Bratsos, I.; Jedner, S.; Gianferrara, T.; Alessio, E. Ruthenium anticancer compounds: challenges and expectations. CHIMIA Int. J. Chem. 2007, 61(11), 692–697. https://doi.org/10.2533/chimia.2007.692.Suche in Google Scholar

Bergamo, A.; Gaiddon, C.; Schellens, J. H. M.; Beijnen, J. H.; Sava, G. Approaching tumour therapy beyond platinum drugs: status of the art and perspectives of ruthenium drug candidates. J. Inorg. Biochem. 2012, 106(1), 90–99.https://doi.org/10.1016/j.jinorgbio.2011.09.030.Suche in Google Scholar PubMed

Batchelor, L. K.; Păunescu, E.; Soudani, M. N.; Scopelliti, R.; Dyson, P. J. Influence of the linker length on the cytotoxicity of homobinuclear ruthenium (II) and gold (I) complexes. Inorg. Chem. 2017, 56(16), 9617–9633.https://doi.org/10.1021/acs.inorgchem.7b01082.Suche in Google Scholar PubMed

Brabec, V.; Nováková, O. DNA binding mode of ruthenium complexes and relationship to tumor cell toxicity. Drug Resist. Updates 2006, 9(3), 111–122.https://doi.org/10.1016/j.drup.2006.05.002.Suche in Google Scholar PubMed

Cervello, M.; Bachvarov, D.; Lampiasi, N.; Cusimano, A.; Azzolina, A.; McCubrey, J. A.; Montalto, G. Molecular mechanisms of sorafenib action in liver cancer cells. Cell Cycle 2012, 11(15), 2843–2855. https://doi.org/10.4161/cc.21193.Suche in Google Scholar PubMed

Coverdale, J. P.; Laroiya-McCarron, T.; Romero-Canelón, I. Designing ruthenium anticancer drugs: what have we learnt from the key drug candidates? INORGA 2019, 7(3), 31.https://doi.org/10.3390/inorganics7030031.Suche in Google Scholar

Clarke, M. J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev. 2002, 232(1-2), 69–93.https://doi.org/10.1016/s0010-8545(02)00025-5.Suche in Google Scholar

de Carvalho, N. C.; Neves, S. P.; Dias, R. B.; Valverde, L. D. F.; Sales, C. B.; Rocha, C. A.; Soares, M. B.; dos Santos, E. R.; Oliveira, R. M.; Carlos, R. M. A novel ruthenium complex with xanthoxylin induces S-phase arrest and causes ERK1/2-mediated apoptosis in HepG2 cells through a p53-independent pathway. Cell Death Dis. 2018, 9(2), 79.https://doi.org/10.1038/s41419-017-0104-6.Suche in Google Scholar PubMed PubMed Central

Chen, J.; Zhang, Y.; Li, G.; Peng, F.; Jie, X.; She, J.; Dongye, G.; Zou, Z.; Rong, S.; Chen, L. Cytotoxicity in vitro, cellular uptake, localization and apoptotic mechanism studies induced by ruthenium (II) complex. JBIC J. Biol. Inorg. Chem. 2018, 23(2), 261–275.https://doi.org/10.1007/s00775-017-1528-2.Suche in Google Scholar PubMed

Carlos Lima, J.; Rodriguez, L. Phosphine-gold (I) compounds as anticancer agents: general description and mechanisms of action. Anti Cancer Agents Med. Chem. 2011, 11(10), 921–928.https://doi.org/10.2174/187152011797927670.Suche in Google Scholar PubMed

Chen, L.; Li, G.; Peng, F.; Jie, X.; Dongye, G.; Cai, K.; Feng, R.; Li, B.; Zeng, Q.; Lun, K. The induction of autophagy against mitochondria-mediated apoptosis in lung cancer cells by a ruthenium (II) imidazole complex. Oncotarget 2016, 7(49), 80716.https://doi.org/10.18632/oncotarget.13032.Suche in Google Scholar PubMed PubMed Central

Corte-Rodríguez, M.; Espina, M.; Sierra, L.; Blanco, E.; Ames, T.; Montes-Bayón, M.; Sanz-Medel, A. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: comparison of different Pt-containing drugs. Biochem. Pharmacol. 2015, 98(1), 69–77.10.1016/j.bcp.2015.08.112Suche in Google Scholar PubMed

Chen, J.-C.; Zhang, Y.; Jie, X.-M.; She, J.; Dongye, G.-Z.; Zhong, Y.; Deng, Y.-Y.; Wang, J.; Guo, B.-Y.; Chen, L.-M. Ruthenium (II) salicylate complexes inducing ROS-mediated apoptosis by targeting thioredoxin reductase. J. Inorg. Biochem. 2019, 193, 112–123.https://doi.org/10.1016/j.jinorgbio.2019.01.011.Suche in Google Scholar PubMed

Côrte-Real, L.; Teixeira, R. G.; Gírio, P.; Comsa, E.; Moreno, A.; Nasr, R.; Baubichon-Cortay, H.; Avecilla, F.; Marques, F.; Robalo, M. P. Methyl-cyclopentadienyl ruthenium compounds with 2, 2′-bipyridine derivatives display strong anticancer activity and multidrug resistance potential. Inorg. Chem. 2018, 57(8), 4629–4639.10.1021/acs.inorgchem.8b00358Suche in Google Scholar PubMed

Deng, Z.; Gao, P.; Yu, L.; Ma, B.; You, Y.; Chan, L.; Mei, C.; Chen, T. Ruthenium complexes with phenylterpyridine derivatives target cell membrane and trigger death receptors-mediated apoptosis in cancer cells. Biomaterials 2017, 129, 111–126.https://doi.org/10.1016/j.biomaterials.2017.03.017.Suche in Google Scholar PubMed

Dredge, K.; Hammond, E.; Handley, P.; Gonda, T.; Smith, M.; Vincent, C.; Brandt, R.; Ferro, V.; Bytheway, I. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br. J. Cancer 2011, 104(4), 635–642.https://doi.org/10.1038/bjc.2011.11.Suche in Google Scholar PubMed PubMed Central

Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136(5), E359–E386.https://doi.org/10.1002/ijc.29210.Suche in Google Scholar PubMed

Ferlay, J.; Colombet, M.; Soerjomataram, I.; Parkin, D. M.; Piñeros, M.; Znaor, A.; Bray, F. Cancer statistics for the year 2020: an overview. Int. J. Cancer 2021, 149(4), 778–789. https://doi.org/10.1002/ijc.33588.Suche in Google Scholar PubMed

Franzblau, S. G.; Witzig, R. S.; McLaughlin, J. C.; Torres, P.; Madico, G.; Hernandez, A.; Degnan, M. T.; Cook, M. B.; Quenzer, V. K.; Ferguson, R. M. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol. 1998, 36(2), 362–366.https://doi.org/10.1128/jcm.36.2.362-366.1998.Suche in Google Scholar

Golbaghi, G.; Castonguay, A. Rationally designed ruthenium complexes for breast cancer therapy. Molecules 2020, 25(2), 265.https://doi.org/10.3390/molecules25020265.Suche in Google Scholar PubMed PubMed Central

De Grandis, R. A.; Dos Santos, P. W. D. S.; de Oliveira, K. M.; Machado, A. R. T.; Aissa, A. F.; Batista, A. A.; Antunes, L. M. G.; Pavan, F. R. Novel lawsone-containing ruthenium (II) complexes: synthesis, characterization and anticancer activity on 2D and 3D spheroid models of prostate cancer cells. Bioorg. Chem. 2019, 85, 455–468.https://doi.org/10.1016/j.bioorg.2019.02.010.Suche in Google Scholar PubMed

Groessl, M.; Hartinger, C. G.; Dyson, P. J.; Keppler, B. K. CZE–ICP-MS as a tool for studying the hydrolysis of ruthenium anticancer drug candidates and their reactivity towards the DNA model compound dGMP. J. Inorg. Biochem. 2008, 102(5-6), 1060–1065.https://doi.org/10.1016/j.jinorgbio.2007.11.018.Suche in Google Scholar PubMed

Hosseini, F. S.; Falahati-Pour, S. K.; Hajizadeh, M. R.; Khoshdel, A.; Mirzaei, M. R.; Ahmadirad, H.; Behroozi, R.; Jafari, N.; Mahmoodi, M. Persian shallot, Allium hirtifolium Boiss, induced apoptosis in human hepatocellular carcinoma cells. Cytotechnology 2017, 69(4), 551–563.https://doi.org/10.1007/s10616-017-0093-4.Suche in Google Scholar PubMed PubMed Central

Harun, S. N.; Ahmad, H.; Lim, H. N.; Chia, S. L.; Gill, M. R. Synthesis and optimization of mesoporous silica nanoparticles for ruthenium polypyridyl drug delivery. Pharmaceutics 2021, 13(2), 150.https://doi.org/10.3390/pharmaceutics13020150.Suche in Google Scholar PubMed PubMed Central

Haghdoost, M.; Golbaghi, G.; Létourneau, M.; Patten, S. A.; Castonguay, A. Lipophilicity-antiproliferative activity relationship study leads to the preparation of a ruthenium (II) arene complex with considerable in vitro cytotoxicity against cancer cells and a lower in vivo toxicity in zebrafish embryos than clinically approved cis-platin. Eur. J. Med. Chem. 2017, 132, 282–293.https://doi.org/10.1016/j.ejmech.2017.03.029.Suche in Google Scholar PubMed

Huang, H.; Zhang, P.; Chen, Y.; Qiu, K.; Jin, C.; Ji, L.; Chao, H. Synthesis, characterization and biological evaluation of labile intercalative ruthenium (II) complexes for anticancer drug screening. Dalton Trans. 2016, 45(33), 13135–13145.https://doi.org/10.1039/c6dt01270a.Suche in Google Scholar PubMed

Irfan, M.; Rehman, R.; Razali, M. R.; Iqbal, M. A. Organotellurium compounds: an overview of synthetic methodologies. Rev. Inorg. Chem. 2020, 1, published ahead of print; https://doi.org/10.1515/revic-2020-0006.Suche in Google Scholar

Jeon, J.; Lee, S.; Kim, H.; Kang, H.; Youn, H.; Jo, S.; Youn, B.; Kim, H. Y. Revisiting platinum-based anticancer drugs to overcome gliomas. Int. J. Mol. Sci. 2021, 22(10), 5111. https://doi.org/10.3390/ijms22105111.Suche in Google Scholar PubMed PubMed Central

Kenny, R. G.; Marmion, C. J. Toward multi-targeted platinum and ruthenium drugs—a new paradigm in cancer drug treatment regimens? Chem. Rev. 2019, 119(2), 1058–1137.https://doi.org/10.1021/acs.chemrev.8b00271.Suche in Google Scholar PubMed

Karmakar, J.; Nandy, P.; Das, S.; Bhattacharya, D.; Karmakar, P.; Bhattacharya, S. Utilization of Guanidine-based ancillary ligands in arene–ruthenium complexes for selective cytotoxicity. ACS Omega 2021, 6(12), 8226–8238.https://doi.org/10.1021/acsomega.0c06265.Suche in Google Scholar PubMed PubMed Central

Ke, N.; Xi, B.; Ye, P.; Xu, W.; Zheng, M.; Mao, L.; Wu, M.-J.; Zhu, J.; Wu, J.; Zhang, W. Screening and identification of small molecule compounds perturbing mitosis using time-dependent cellular response profiles. Anal. Chem. 2010, 82(15), 6495–6503.https://doi.org/10.1021/ac1007877.Suche in Google Scholar PubMed

Li, X.; Ramadori, P.; Pfister, D.; Seehawer, M.; Zender, L.; Heikenwalder, M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat. Rev. Cancer 2021, 21(9), 541–557.https://doi.org/10.1038/s41568-021-00383-9.Suche in Google Scholar PubMed

Levina, A.; Mitra, A.; Lay, P. A. Recent developments in ruthenium anticancer drugs. Metallomics 2009, 1(6), 458–470. https://doi.org/10.1039/b904071d.Suche in Google Scholar PubMed

Li, F.; Collins, J. G.; Keene, F. R. Ruthenium complexes as antimicrobial agents. Chem. Soc. Rev. 2015, 44(8), 2529–2542. https://doi.org/10.1039/c4cs00343h.Suche in Google Scholar PubMed

Li, Y.; Wu, Q.; Yu, G.; Li, L.; Zhao, X.; Huang, X.; Mei, W. Polypyridyl Ruthenium (II) complex-induced mitochondrial membrane potential dissipation activates DNA damage-mediated apoptosis to inhibit liver cancer. Eur. J. Med. Chem. 2019, 164, 282–291.https://doi.org/10.1016/j.ejmech.2018.12.041.Suche in Google Scholar PubMed

Lang, X.-X.; Yu, Q.-Q.; Li, H.-Y.; Luo, Y.; Yu, X.-F.; Wang, H.-J.; Wang, M.-Q. Identification of a non-planar imidazole-cored small molecule for selective telomeric G4 DNA targeting. Dyes Pigments 2022, 197, 109901.https://doi.org/10.1016/j.dyepig.2021.109901.Suche in Google Scholar

Liu, X.; Huang, J.; Tang, Y.; Shen, Y.; Lu, J. Topoisomerase I inhibitory and photocleavage activity of non‐dppz DNA ‘light switches’ based on ruthenium complexes containing nitro group. Appl. Organomet. Chem. 2018, 32(8), e4423.https://doi.org/10.1002/aoc.4423.Suche in Google Scholar

Lu, Y.; Shen, T.; Yang, H.; Gu, W. Ruthenium complexes induce HepG2 human hepatocellular carcinoma cell apoptosis and inhibit cell migration and invasion through regulation of the Nrf2 pathway. Int. J. Mol. Sci. 2016, 17(5), 775.https://doi.org/10.3390/ijms17050775.Suche in Google Scholar PubMed PubMed Central

Lagunin, A. A.; Romanova, M. A.; Zadorozhny, A. D.; Kurilenko, N. S.; Shilov, B. V.; Pogodin, P. V.; Ivanov, S. M.; Filimonov, D. A.; Poroikov, V. V. Comparison of quantitative and qualitative (Q) SAR models created for the prediction of Ki and IC50 values of antitarget inhibitors. Front. Pharmacol. 2018, 9, 1136.https://doi.org/10.3389/fphar.2018.01136.Suche in Google Scholar PubMed PubMed Central

Motswainyana, W. M.; Ajibade, P. A. Anticancer activities of mononuclear ruthenium (II) coordination complexes. Adv. Chem. 2015, 2015, 1–21,.https://doi.org/10.1155/2015/859730.Suche in Google Scholar

Maschke, M.; Alborzinia, H.; Lieb, M.; Wölfl, S.; Metzler‐Nolte, N. Structure–activity relationship of Trifluoromethyl‐containing Metallocenes: electrochemistry, lipophilicity, cytotoxicity, and ROS production. ChemMedChem 2014, 9(6), 1188–1194.https://doi.org/10.1002/cmdc.201402001.Suche in Google Scholar PubMed

Mårtensson, A. K.; Lincoln, P. Effects of methyl substitution on DNA binding enthalpies of enantiopure Ru (phenanthroline) 2 dipyridophenazine 2+ complexes. Phys. Chem. Chem. Phys. 2018, 20(16), 11336–11341.10.1039/C8CP01151FSuche in Google Scholar PubMed

Morak-Młodawska, B.; Pluta, K.; Jeleń, M. Evaluation of the lipophilicity of new anticancer 1, 2, 3-Triazole-dipyridothiazine hybrids using RP TLC and different computational methods. Processes 2020, 8(7), 858.10.3390/pr8070858Suche in Google Scholar

Mohan, N.; Muthumari, S.; Ramesh, R. Synthesis, structure and anticancer activity of (η6-benzene) ruthenium (II) complexes containing aroylhydrazone ligands. J. Organomet. Chem. 2016, 807, 45–51.https://doi.org/10.1016/j.jorganchem.2016.01.033.Suche in Google Scholar

Marker, S. C.; MacMillan, S. N.; Zipfel, W. R.; Li, Z.; Ford, P. C.; Wilson, J. J. Photoactivated in vitro anticancer activity of rhenium (I) tricarbonyl complexes bearing water-soluble phosphines. Inorg. Chem. 2018, 57(3), 1311–1331.https://doi.org/10.1021/acs.inorgchem.7b02747.Suche in Google Scholar PubMed PubMed Central

Nagy, E.; Liu, Y.; Prentice, K. J.; Sloop, K. W.; Sanders, P. E.; Batchuluun, B.; Hammond, C. D.; Wheeler, M. B.; Durham, T. B. Synthesis and characterization of urofuranoic acids: in vivo metabolism of 2-(2-Carboxyethyl)-4-methyl-5-propylfuran-3-carboxylic acid (CMPF) and effects on in vitro insulin secretion. J. Med. Chem. 2017, 60(5), 1860–1875.https://doi.org/10.1021/acs.jmedchem.6b01668.Suche in Google Scholar PubMed

Novakova, O.; Kasparkova, J.; Vrana, O.; van Vliet, P. M.; Reedijk, J.; Brabec, V. Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes. Biochemistry 1995, 34(38), 12369–12378.https://doi.org/10.1021/bi00038a034.Suche in Google Scholar PubMed

Nepali, K.; Lee, H.-Y.; Liou, J.-P. Nitro-group-containing drugs. J. Med. Chem. 2018, 62(6), 2851–2893. https://doi.org/10.1021/acs.jmedchem.8b00147.Suche in Google Scholar PubMed

Oun, R.; Moussa, Y. E.; Wheate, N. J. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 2018, 47(19), 6645–6653.https://doi.org/10.1039/c8dt00838h.Suche in Google Scholar PubMed

Oldfield, S. P.; Hall, M. D.; Platts, J. A. Calculation of lipophilicity of a large, diverse dataset of anticancer platinum complexes and the relation to cellular uptake. J. Med. Chem. 2007, 50(21), 5227–5237.https://doi.org/10.1021/jm0708275.Suche in Google Scholar PubMed

Piccolo, M.; Ferraro, M. G.; Raucci, F.; Riccardi, C.; Saviano, A.; Russo Krauss, I.; Trifuoggi, M.; Caraglia, M.; Paduano, L.; Montesarchio, D. Safety and efficacy evaluation in vivo of a cationic nucleolipid nanosystem for the nanodelivery of a ruthenium (III) complex with superior anticancer bioactivity. Cancers 2021, 13(20), 5164.https://doi.org/10.3390/cancers13205164.Suche in Google Scholar PubMed PubMed Central

Popolin, P. C.; Cominetti, M. R. A review of ruthenium complexes activities on breast cancer cells. Mini Rev. Med. Chem. 2017, 17(15), 1435–1441.https://doi.org/10.2174/1389557517666170206151218.Suche in Google Scholar PubMed

Reedijk, J. Platinum anticancer coordination compounds: study of DNA binding inspires new drug design. Eur. J. Inorg. Chem. 2009, 2009(10), 1303–1312.https://doi.org/10.1002/ejic.200900054.Suche in Google Scholar

van Rijt, S. H.; Sadler, P. J. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov. Today 2009, 14(23), 1089–1097.https://doi.org/10.1016/j.drudis.2009.09.003.Suche in Google Scholar PubMed PubMed Central

Ruiz, J.; Rodriguez, V.; Cutillas, N.; Espinosa, A.; Hannon, M. J. A potent ruthenium (II) antitumor complex bearing a lipophilic levonorgestrel group. Inorg. Chem. 2011, 50(18), 9164–9171.https://doi.org/10.1021/ic201388n.Suche in Google Scholar PubMed

Reedijk, B. J. Metal-ligand exchange kinetics in platinum and ruthenium complexes. Platin. Met. Rev. 2008, 52(1), 2–11. https://doi.org/10.1595/147106708x255987.Suche in Google Scholar

Ren, F.; Ji, P. Recent advances in the application of metal–organic frameworks for polymerization and oligomerization reactions. Catalysts 2020, 10(12), 1441.https://doi.org/10.3390/catal10121441.Suche in Google Scholar

Roy, S.; Hagen, K. D.; Maheswari, P. U.; Lutz, M.; Spek, A. L.; Reedijk, J.; van Wezel, G. P. Phenanthroline derivatives with improved selectivity as DNA‐targeting anticancer or antimicrobial drugs. ChemMedChem: Chem. Enabl. Drug Discov. 2008, 3(9), 1427–1434.https://doi.org/10.1002/cmdc.200800097.Suche in Google Scholar PubMed

Shahzad, K.; Majid, A. S. A.; Khan, M.; Iqbal, M. A.; Ali, A. Recent advances in the synthesis of (99mTechnetium) based radio-pharmaceuticals. Rev. Inorg. Chem. 2021, 41(3), 151–198.10.1515/revic-2020-0021Suche in Google Scholar

Silvestri, S.; Cirilli, I.; Marcheggiani, F.; Dludla, P.; Lupidi, G.; Pettinari, R.; Marchetti, F.; Di Nicola, C.; Falcioni, G.; Marchini, C. Evaluation of anticancer role of a novel ruthenium (II)-based compound compared with NAMI-A and cisplatin in impairing mitochondrial functionality and promoting oxidative stress in triple negative breast cancer models. Mitochondrion 2021, 56, 25–34. https://doi.org/10.1016/j.mito.2020.11.004.Suche in Google Scholar PubMed

Southam, H. M.; Butler, J. A.; Chapman, J. A.; Poole, R. K. The microbiology of ruthenium complexes. Adv. Microb. Physiol. 2017, 71, 1–96. https://doi.org/10.1016/bs.ampbs.2017.03.001.Suche in Google Scholar PubMed

Subarkhan, M. K. M.; Ramesh, R. Ruthenium (II) arene complexes containing benzhydrazone ligands: synthesis, structure and antiproliferative activity. Inorg. Chem. Front. 2016, 3(10), 1245–1255.https://doi.org/10.1039/c6qi00197a.Suche in Google Scholar

Savić, N. D.; Milivojevic, D. R.; Glišić, B. Đ.; Ilic-Tomic, T.; Veselinovic, J.; Pavic, A.; Vasiljevic, B.; Nikodinovic-Runic, J.; Djuran, M. I. A comparative antimicrobial and toxicological study of gold (III) and silver (I) complexes with aromatic nitrogen-containing heterocycles: synergistic activity and improved selectivity index of Au (III)/Ag (I) complexes mixture. RSC Adv. 2016, 6(16), 13193–13206.10.1039/C5RA26002GSuche in Google Scholar

Shad, H.; Hussain, A.; Shahzad, K.; Abeeha, H. G. Multi-component synthesis of novel diazoles: their characterization and biological evaluation. Arc Org Inorg Chem Sci 2018, 1(2), 107. https://doi.org/10.32474/aoics.2018.01.000107.Suche in Google Scholar

Testa, B.; Crivori, P.; Reist, M.; Carrupt, P.-A. The influence of lipophilicity on the pharmacokinetic behavior of drugs: concepts and examples. Perspect. Drug Discov. Des. 2000, 19(1), 179–211.https://doi.org/10.1023/a:1008741731244.10.1023/A:1008741731244Suche in Google Scholar

Wong, M. C. S.; Jiang, J. Y.; Goggins, W. B.; Liang, M.; Fang, Y.; Fung, F. D. H.; Leung, C.; Wang, H. H. X.; Wong, G. L. H.; Wong, V. W. S.; Chan, H. L. Y. International incidence and mortality trends of liver cancer: a global profile. Sci. Rep. 2017, 7(1), 45846. https://doi.org/10.1038/srep45846.Suche in Google Scholar PubMed PubMed Central

Wang, J.; Tao, J.; Jia, S.; Wang, M.; Jiang, H.; Du, Z. The protein-binding behavior of platinum anticancer drugs in blood revealed by mass spectrometry. Pharmaceuticals 2021, 14(2), 104.https://doi.org/10.3390/ph14020104.Suche in Google Scholar PubMed PubMed Central

Wan, D.; Tang, B.; Wang, Y.-J.; Guo, B.-H.; Yin, H.; Yi, Q.-Y.; Liu, Y.-J. Synthesis and anticancer properties of ruthenium (II) complexes as potent apoptosis inducers through mitochondrial disruption. Eur. J. Med. Chem. 2017, 139, 180–190.https://doi.org/10.1016/j.ejmech.2017.07.066.Suche in Google Scholar PubMed

Xu, Z.; Kong, D.; He, X.; Guo, L.; Ge, X.; Liu, X.; Zhang, H.; Li, J.; Yang, Y.; Liu, Z. Mitochondria-targeted half-sandwich ruthenium II diimine complexes: anticancer and antimetastasis via ROS-mediated signalling. Inorg. Chem. Front. 2018, 5(9), 2100–2105.https://doi.org/10.1039/c8qi00476e.Suche in Google Scholar

Yan, Y. K.; Melchart, M.; Habtemariam, A.; Sadler, P. J. Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes. Chem. Commun. 2005, 2005(38), 4764–4776; https://doi.org/10.1039/b508531b.Suche in Google Scholar PubMed

Yang, X.; Chen, L.; Liu, Y.; Yang, Y.; Chen, T.; Zheng, W.; Liu, J.; He, Q.-Y. Ruthenium methylimidazole complexes induced apoptosis in lung cancer A549 cells through intrinsic mitochondrial pathway. Biochimie 2012, 94(2), 345–353.https://doi.org/10.1016/j.biochi.2011.07.025.Suche in Google Scholar PubMed

Zhao, X.; Li, L.; Yu, G.; Zhang, S.; Li, Y.; Wu, Q.; Huang, X.; Mei, W. Nucleus-enriched ruthenium Polypyridine complex acts as a Potent inhibitor to suppress triple-negative breast cancer Metastasis in vivo. Comput. Struct. Biotechnol. J. 2019, 17, 21–30.https://doi.org/10.1016/j.csbj.2018.11.010.Suche in Google Scholar PubMed PubMed Central